Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1014616 | 0.95 | IDO1 (0.54) | IDO1PNMTTAAR1LMNATSHR | |
| Hydrochloric Acid SCHEMBL30719147 | 0.95 | IDO1 (0.54) | IDO1PNMTTAAR1LMNATSHR | |
| Bromide SCHEMBL11300757 | 0.80 | PNMT (0.60) | IDO1PNMTTAAR1TSHRCYP1A2 | |
| Bromide SCHEMBL1045488 | 0.78 | PNMT (0.41) | IDO1PNMTTAAR1LMNATSHR | |
| Pivalate SCHEMBL9953463 | 0.77 | NPC1 (0.43) | IDO1PNMTLMNATSHRPKM | |
| Hydrochloric Acid SCHEMBL1043017 | 0.75 | PNMT (0.60) | IDO1PNMTTAAR1TSHRCYP1A2 | |
| SCHEMBL6740216 | 0.75 | TAAR1 (0.71) | IDO1PNMTTAAR1LMNATSHR | |
| SCHEMBL29519238 | 0.75 | IDO1 (0.62) | IDO1PNMTTAAR1LMNATSHR | |
| SCHEMBL672407 | 0.75 | IDO1 (0.62) | IDO1PNMTTAAR1LMNATSHR | |
| Bromide SCHEMBL27458904 | 0.74 | IDO1 (0.54) | IDO1PNMTTAAR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9034866-B2 | Tricyclic compounds and methods of use therefor | GENENTECH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| CN-104284899-A | Tricyclic compounds and methods of use therefor | HOFFMANN LA ROCHE | 2015-01-14 | — | — | CN | disclosed |
| EP-2814830-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| CN-103443102-A | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC | 2013-12-11 | — | — | CN | disclosed |
| CN-103384669-A | Bicyclic inhibitors of ALK | ABBVIE LAB | 2013-11-06 | — | — | CN | disclosed |
| CN-103380117-A | Picolinamide inhibitors of kinases | ABBOTT LAB | 2013-10-30 | — | — | CN | disclosed |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097684-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20080194598-A1 | Pyrimidine Carboxylic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | CHRM2 159/4885IDO1 2726/4885PNMT 3122/4885 |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | CHRM2 3092/4885IDO1 2470/4885PNMT 2443/4885 |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | CHRM2 674/4885IDO1 1775/4885PNMT 3078/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | CHRM2 1814/4885IDO1 1561/4885PNMT 3641/4885 |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | CHRM2 159/4885IDO1 2726/4885PNMT 3122/4885 |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ALK, BRAF, BMX | CHRM2 2244/4885IDO1 3636/4885PNMT 2776/4885 |
| US-20080194598-A1 | Pyrimidine Carboxylic Acid Derivatives and Use Thereof | DPYD, TYMP, TYMS | CHRM2 3324/4885IDO1 3216/4885PNMT 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.